Business Context and Reporting Period
This Form 8-K Current Report for MediciNova, Inc. covers events occurring on June 11, 2009, and June 12, 2009. The filing details corporate governance changes, including the entry into a material consulting agreement, the resignation of key executive officers and a director, and the results of the Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is the compensation rate for a new consulting agreement.
- Consulting Fee: $27,500 per month for services related to product development programs.
- Agreement Duration: Four months.
Material Changes
Executive and Board Departures
- Chief Development Officer: Richard E. Gammans, Ph.D., resigned effective June 12, 2009.
- Chief Medical Officer: Michael E. Kalafer, M.D., resigned effective June 12, 2009.
- Audit Committee Member: Alan W. Dunton, M.D., resigned from the Audit Committee effective June 12, 2009.
- Director Term Expiration: Daniel Vapnek, Ph.D., did not stand for reelection; his term expired immediately following the June 11, 2009 meeting.
New Agreements and Appointments
- Consulting Agreement: Entered into with Danerius, LLC (an affiliate of Director Alan W. Dunton) to provide consulting services.
- Director Election: Yuichi Iwaki, M.D., Ph.D., was elected as the sole Class II director until 2012.
- Auditor Ratification: Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2009.
Outlook, Risks, and Contingencies
NASDAQ Compliance Issue
Following Dr. Dunton's resignation, the Audit Committee consists of only two members, falling below the NASDAQ Marketplace Rule 5605(c)(2) minimum of three members. The Company notified NASDAQ of this deficiency on June 15, 2009.
- Cure Period: The Company has up to one year (until June 12, 2010) or until the next annual shareholder meeting to fill the vacancy and regain compliance.
Management Commentary
The filing highlights Dr. Dunton's extensive background in biotechnology and pharmaceutical development, noting his role in the approval of over 20 commercial drug products, as justification for the new consulting arrangement.
Investor Verification Checklist
- Verify the impact of the simultaneous resignations of the Chief Development Officer and Chief Medical Officer on ongoing product development programs.
- Confirm the timeline for appointing a new Audit Committee member to resolve the NASDAQ listing deficiency.
- Review the specific scope of services to be provided by Danerius, LLC under the new consulting agreement.
- Monitor the Company's ability to maintain compliance with NASDAQ listing standards during the cure period.